eGenesis Announces $ 125 Million Series C Funding

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) – eGenesis, a gene editing and genome engineering company developing organs, tissues and cells compatible with humans, today announced the conclusion in a Series C financing of $ 125 million. The funding will be used to integrate the company’s flagship kidney and islet transplant programs in human proof-of-concept studies. In addition, the funds will be used for the continued development of the company’s proprietary gene editing platform and the scaling up of GMP production.

Funding from major healthcare investors included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management and Osage University Partners. Existing investors including Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures and Alta Partners participated.

Concurrent with the closing of the financing, Isaac Ciechanover, MD, of Polaris Partners, and Mark Pruzanski, MD, founder and former CEO of Intercept Pharmaceuticals, have joined the board of directors of eGenesis.

“We are proud of the progress we are making in our mission to help solve the global organ shortage,” said Paul Sekhri, President and CEO of eGenesis. “We thank our new and current investors for their vote of confidence. With this funding, we are now well positioned to address two of the greatest disease burdens in the United States and in global health systems. “

“EGenesis has developed a scientific platform that will transform transplant medicine,” added Srini Akkaraju, MD, PhD, Founder and Managing Partner of Samsara BioCapital. “We are excited about the advancements eGenesis is making in kidney and islet cell transplantation, which could address the rapidly growing unmet needs of patients with kidney disease and type 1 diabetes. “

About transplantation and xenotransplantation
The demand for rescue bodies far exceeds the available supply. In the United States alone, more than 110,000 people are on the national transplant list. 20 people die every day due to the lack of organs available for transplantation and every 10 minutes a new name is added to the national transplant waiting list.

The concept of xenotransplantation (transplantation of organs, tissues and cells from one species to another) has been explored for decades, with the pig being considered the most suitable donor for humans. However, obstacles in virology and immunology have prevented the field from going beyond early preclinical research. With the advent of advanced gene editing technologies, meeting these historic challenges is now within reach.

About eGenesis
The goal of eGenesis is to transform the field of transplantation by providing safe and efficient organs, tissues and cells to patients in need. The company is harnessing cutting-edge gene editing technologies to address key issues that have hampered xenotransplantation to date. EGenesis’ development pipeline includes core programs for kidney and islet cell transplantation, as well as early stage programs focused on other solid organs. Learn more about egenesisbio.com.

Contacts:
Investors
Jean Grimaldi
Burns McClellan, Inc.
212-213-0006 ext. 362
[email protected]

Media
Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, Inc.
212-213-0006 ext 315/364
[email protected] / [email protected]

More Stories
China’s 2021 soybean imports fall 3.8% on lower margins and weak demand